The agreement will allow Bristol-Myers Squibb to expand deployment of DynoChem process modeling software throughout its Research and Development group and for scale-up into manufacturing.
Bristol-Myers Squibb noted that in meeting the challenges inherent in the scale-up of synthetic pharmaceutical processes, operation modeling allows the company to make use of knowledge and resources to answer critical questions.
In addition, the incorporation of modeling technologies such as DynoChem across Bristol-Myers Squibb’s process development enterprise helps achieve the company’s development goals.
PFD Managing Director Dr. Joe Hannon said, “We are pleased to have the opportunity to expand our relationship with BMS and continue our commitment to their pharmaceutical product development effort. We believe this agreement further validates DynoChem’s success in achieving our customers’ goals of accelerating process development and lowering drug development costs.”